Amyloid fibril formation in microwell plates for screening of inhibitors

References

• Carrell R W, Lomas D A. Conformational disease. Lancet 1997; 350: 134–138
   PubMed Web of Science ®Google Scholar
• Stone M J. Amyloidosis: a final common pathway for protein deposition in tissues. Blood 1990; 75: 531–545
   PubMed Web of Science ®Google Scholar
• Sipe J D. Amyloidosis. Ann Rev Biochem 1992; 61: 947–975
   PubMed Web of Science ®Google Scholar
• Edgington S M. Amyloid plaque and diabetes. Biotechnology 1994; 12: 591–594
   PubMedGoogle Scholar
• Gallo G, Picken M, Buxbaum J, Frangione B. The spectrum of monoclonal immunoglobulin deposition disease associated with immunocytic dyscrasias. Semin Hematol 1989; 26: 234–245
   PubMed Web of Science ®Google Scholar
• Buxbaum J N, Chuba J V, Hellman G C, Solomon A, Gallo G R. Monoclonal immunoglobulin deposition disease: light chain and light and heavy chain deposition diseases and their relation to light chain amyloidosis. Ann Int Med 1990; 112: 455–464
   PubMed Web of Science ®Google Scholar
• Orfila C, Lepert J-C, Modesto A, Bernadet P, Suc J-M. Fanconi's syndrome, kappa light-chain myeloma, non-amyloid fibrils and cytoplasmic crystals in renal tubular epithelium. Am J Nephrol 1991; 11: 345–349
   PubMedGoogle Scholar
• Stevens F J, Solomon A, Schiffer M. Bence Jones proteins: a powerful tool for the fundamental study of protein chemistry and pathophysiology. Biochem 1991; 30: 6803–6805
   PubMed Web of Science ®Google Scholar
• Aucouturier P, Bauwens M, Khamlichi A A, Denoroy L, Spinelli S, Touchard G, Preud'homme J-L, Cogn C M. Monoclonal Ig L chain and L chain V domain fragment crystallization in myeloma-associated Fanconi's syndrome. J Immunol 1993; 150: 3561–3568
   PubMed Web of Science ®Google Scholar
• Solomon A, Weiss D T. Ominous consequences of immunoglobulin deposition. New Engl J Med 1993; 329: 1422–1423
   PubMedGoogle Scholar
• Bellotti V, Merlini G. Toward understanding the molecular pathogenesis of monoclonal immunoglobulin light-chain deposition. Nephrol Dial Transplant 1996; 11: 1708–1711
   PubMedGoogle Scholar
• Bellotti V, Stoppini M, Mangionc P P, Fornasieri A, Min L., Merlini G, Ferri G. Structural and functional characterization of three human immunoglobulin k light chains with different pathological implications. Biochem Biophys Ada 1996; 1317: 161–167
   PubMed Web of Science ®Google Scholar
• Schiffer M. Molecular anatomy and the pathological expression of antibody light chains. Am J Pathol 1996; 148: 1339–1344
   PubMed Web of Science ®Google Scholar
• Dhodapkar M, Merlini V. G, Solomon A. Biology and therapy of immunoglobulin deposition diseases [Review]. Hemat/Oncol Clin Nor Amer 1997; 11: 89–110
   PubMed Web of Science ®Google Scholar
• Lambert M P, Barlow A K, Chromy B A, Edwards C, Freed R, Liosatos M, Morgan T E, Rozovsky I, Trommer B, Viola K L, Wals P, Zhang C, Finch C E, Krafft G A, Klein W L. Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998; 95: 6448–6453
   PubMed Web of Science ®Google Scholar
• Sisodia S, Price D L. Role of the β-amyloid protein in Alzheimer's disease. FASEB J 1995; 9: 366–370
   PubMed Web of Science ®Google Scholar
• Raffen R, Dieckman L J, Szpunar M, Wunschl C, Pokkuluri P R, Dave P, Wilkins Stevens P, Cai X, Schiffer M, Stevens F J. Physicochemical consequences of amino acid variations that contribute to fibril formation by immunoglobulin light chains. Protein Sci 1999; 8: 509–517
   PubMed Web of Science ®Google Scholar
• Stevens F J. Four structural risk factors identify most fibril-forming kappa light chains Amyloid. J Exp Clin Invest 2000; 7: 200–211
   Google Scholar
• Augelli Szafran C E, Walker L C, LeVine H, III. Chapter 3. β-Amyloid as a target for Alzheimer's disease therapy. Annual Reports in Medicinal Chemistry, A M Doherty, 1999; 34: 21–30
   Google Scholar
• Findes M A, Musso G M, Arico-Muendel C C, Benjamin H W, Hundal A M, Lee J-J, Chin J, Kelley M, Wakefield I, Hay-Ward N J, Molineaux S M. Modified-peptide inhibitors of amyloid β-peptide polymerization. Biochem 1999; 38: 6791–6800
   PubMedGoogle Scholar
• Oza V B, Petrassi H M, Purkey H E, Kelly J W. Synthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors. Bioorg & Med Chem Letters 1999; 9: 1–6
   PubMed Web of Science ®Google Scholar
• Baures P W, Peterson S A, Kelly J W. Discovering transthyretin amyloid fibril inhibitors by limited screening. Bioorg & MedChem 1998; 6: 1389–1401
   PubMed Web of Science ®Google Scholar
• Soto C., Sigurdsson E M, Morelli L, Kumar R A, CastaAo E M, Frangione B. β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat Med 1998; 4: 822–826
   PubMed Web of Science ®Google Scholar
• Esler W P, Stimson E R, Ghilardi J R, Felix A M, Lu Y-A, Vinters H V, Mantyh P W, Maggio J E. AD-deposi-tion inhibitor screen using synthetic amyloid. Nat Biotec 1997; 15: 258–263
   PubMed Web of Science ®Google Scholar
• Merlini G, Anesi E, Garini P, Perfetti V, Obici L, Ascari E, Lechuga M H, Capri G, Gianni L. Treatment of AL amyloidosis with 4′-iodo-4′-deoxydoxorubicin: An update. Blood 1999; 93: 1112–1113
   PubMed Web of Science ®Google Scholar
• Bard F, Cannon C, Barbour R, Burke R-L, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T. Peripherally administered antibodies against amyloid &peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000; 6: 916–919
   PubMed Web of Science ®Google Scholar
• Solomon A. Light chains of human immunoglobu-lins. Methods Enzymol 1985; 116: 101–121
   PubMed Web of Science ®Google Scholar
• Pras M, Schubert M, Zucker-Franklin D, Rimon A, Franklin E C. The characterization of soluble amyloid prepared in water. J Clin Invest 1968; 47: 924–933
   PubMed Web of Science ®Google Scholar
• Wilkins Stevens P, Raffen R, Hanson D K, Deng Y-L, Berrios-Hammond M, Westholm F A, Murphy C, Eulitz M, Wetzel R, Solomon A, Schiffer M, Stevens F J. Recombi-nant immunoglobulin variable domains generated from synthetic genes provide a system for in vitro characterization of light chain amyloid proteins. Protein Sci 1995; 4: 421–432
   PubMedGoogle Scholar
• Solomon A, Weiss D T, Murphy C L, Hrncic R, Wall J S, Schell M. Light chain-associated amyloid deposits comprised of a novel k constant domain. Proc Natl Acad Sci USA 1998; 95: 9547–9551
   PubMed Web of Science ®Google Scholar
• Naiki H, Higuchi K, Hosokawa M, Takeda T. Fluo-rometric determination of amyloid fibrils in vitro using the fluorescent dye, Thioflavin T. Anal. Biochem 1989; 177: 244–249
   PubMed Web of Science ®Google Scholar
• Ariyan Z S, Suschitzky H. Heterocyclic compounds of chalcone type. J Chem Soc 1961; 2242–2244
   Google Scholar
• Chen F C, Yang C H, Hsu K K. Synthesis of halogenoflavonoids I. Synthesis of 6-chloro-flavanone and-flavone. J Formosan Sci 1953; 7: 51–53
   Google Scholar
• Chen F C, Hsu K K. Synthesis of halogenoflavonoids II. Synthesis of 2′.3′, 4′-chloro-flavanone and-flavone. J Formosan Sci 1953; 7: 54–56
   Google Scholar
• Chen F C, Lai P C, Hsieh H C. Synthesis of halogenoflavonoids III. Synthesis of 2′-, 3′-, 4′-, 6-bromoflavanones and 6-bromo-flavones. J Formosan Sci. 1953; 7: 57–62
   Google Scholar
• Chen F C, Lin C, Lai S C. Synthesis of halogenoflavonoids IV. Synthesis of 2′-, 3′-, 4′-iodoflavanone and corresponding chalcones. J Formosan Sct 1953; 7: 63–65
   Google Scholar
• Chen F C, Lin C, Tu T T. Synthesis of halogenoflavonoids VII. Synthesis of 2–, 3– and 4-fluoro-2′-oxychalcone. J Formosan Sci 3954; 8: 71–73
   Google Scholar
• Lin Y M, Chen F C, Liang C M. Biflavonyls from drupes of Rhus succedanea. Phytochemistry 1974; 12: 276–277
   Google Scholar
• Lin Y M, Chen F C. Agathisflavone from drupes of Rhus succedanea. Phytochemistry 1974; 13: 657–65
   Google Scholar
• Lin Y M, Chen F C. Robustaflavone from the seed of kernels of Rhus succedanea. Phytochemistry 1974; 13: 1617–1619
   Google Scholar
• Chen F C, Lin Y M. Rhusflavanone. a new biflavanone from the seeds of wax tree. J Chem Soc Perkin Trans 1976; 198–101
   Google Scholar
• Huang D-B, Chang C-H, Ainsworth Johnson C. G, Solomon A, Stevens F J, Schiffer M. Variable domain structure of kIV human light chain LEN: high homology to the murine light chain McPC603. Mol Immunol 1997; 34: 1291–1301
   PubMed Web of Science ®Google Scholar
• Klunk W E, Jacob R F, Mason R P. Quantifying amyloid β-peptide (Aβ) aggregation using the Congo red Aβ (CR-Aβ) spectrophotometric assay. Anal Biochem 1999; 286: 66–76
   Google Scholar
• Naiki H, Nakakuki K. First-order kinetic model of Alzheimers β-amyloid fibril extension in vitro. Lab Invest 1996; 74: 374–383
   PubMed Web of Science ®Google Scholar
• LeVine H, III. Thioflavine T interaction with synthetic Alzheimer's disease β-amyloid peptides: Detection of amyloid aggregation in solution. Protein Sci 1993; 2: 404–410
   PubMed Web of Science ®Google Scholar
• LeVine H, III. Thioflavine T interaction with amyloid β-sheet structures Amyloid. J Exp Clin Invest 1995; 2: 1–6
   Web of Science ®Google Scholar
• Zagorski M G, Yang J, Shao H, Ma K, Zeng H, Hong A. Methodological and chemical factors affecting amyloid β-peptide amyloidogenicity. Methods in Enzymology 309 Amyloid, Prions, and other Protein Aggregates, R Wetzel. Academic Press, New York, NY 1999; 189–204
   Google Scholar
• Harper J D, Lansbury P T, Jr. Models of amyloid seeding in Alzheimer's disease and scrapie-mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Ann Rev Biochem 1997; 66: 385–407
   PubMed Web of Science ®Google Scholar
• Lomakin A, Benedek G B, Teplow D B. Monitoring protein assembly using quasielastic light scattering spec-troscopy. Methods in Enzymology 309 Amyloid, Prions, and other Protein Aggregates, R Wetzel. Academic Press, New York, NY 1999; 429–460
   Google Scholar
• Wall J, Solomon A. Flow cytometric characterization of amyloid fibrils. Methods in Enzymology 309 Amyloid, Prions, and other Protein Aggregates, R Wetzel. Academic Press, New York, NY 1999; 460–467
   Google Scholar
• Levine H, III. Stopped-flow kinetics reveal multiple phases of Thioflavin T binding to Alzheinier β (1–40) amyloid fibrils. Arch Biochem & Biophys 1997; 342: 306–316
   PubMed Web of Science ®Google Scholar
• LeVine H, III. Quantification of P-sheet amyloid fibril structures with Thioflavin T. Methods in Enzymology 309 Amyloid, Prions, and other Protein Aggregates, R Wetzel. Academic Press, New York, NY 1999; 274–284
   Google Scholar
• Naiki H, Gejyo F. Kinetic analysis of amyloid fibril formation [Review]. Methods in Enzymology 309 Aniyloid, Prions, and other Protein Aggregates, R Wetzel. Academic Press, New York, NY 1999; 305–318
   Google Scholar
• Walsh D M, Hartley D M, Kusumoto Y, Fezoui Y, Condron M M, Lomakin A, Benedek G B, Selkoe D J, Teplow D U. Amyloid Ij-protein fibrillogenesis-Structure and biological activity of protofibrillar intermediates. J Biol Chem 1999; 274: 25945–25952
   PubMed Web of Science ®Google Scholar
• Mattson M P, Cheng B, Davis D, Bryant D, Lieberburg I, Rydel R E. β-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 1992; 12: 376–389
   PubMed Web of Science ®Google Scholar
• Shen C-L, Murphy R M. Solvent effects on self-assembly of β-amyloid peptide. Siophys J 1995; 69: 640–651
   PubMed Web of Science ®Google Scholar
• Wetzel R. Domain stability in immunoglobulin light chain deposition disorders. Adv Protein Chem 1997; 50: 183–241, and references cited therein
   PubMedGoogle Scholar
• Trombetta E X, Helenius A. Lectins as chaperones in glycoprotein folding. Curr Opin Struct Biol 1998; 8: 587–592
   PubMedGoogle Scholar
• Kelly J W. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr Opin Strict Biol 1998; 8: 101–106
   PubMed Web of Science ®Google Scholar
• Dobson C M. Protein misfolding, evolution and disease. Trends in Biocheni Sci 1999; 24: 329–332
   PubMed Web of Science ®Google Scholar
• Kim Y-S, Wall J S, Meyer J, Murphy C, Randolph T W, Manning M C, Solomon A, Carpenter J F. Thermody-namic modulation of light chain amyloid fibril formation. J Biol Chem 2000; 275: 1570–1574
   PubMed Web of Science ®Google Scholar
• Chang B S, Beauvais R M, Arakawa T, Narhi L O, Dong A, Aparisio D I, Carpenter J F. Formation of an active dimer during storage of interleukin-1 receptor antagonist in aqueous solution. Siophys J 1996; 71: 3399–3406
   PubMedGoogle Scholar
• Kendrick B S, Carpenter J F, Cleland J L, Randolph T W. A transient expansion of the native state precedes aggregation of recombinant human interferon-gamma. Proc Natl AcadSci USA 1998; 95: 14142–14146
   PubMed Web of Science ®Google Scholar
• Miroy G J, Lai Z, Lashuel H A, Peterson S A, Strang C, Kelly J W. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc Natl Acad Sci USA 1996; 93: 15051–15056
   PubMed Web of Science ®Google Scholar
• Peterson S A, Klabunde T, Lashuel H A, Purkey H, Sacchettini J C, Kelly J W. Inhibiting transthyretin conforma-tional changes that lead to amyloid fibril formation. Proc Natl Acad Sci USA 1998; 95: 12956–12960
   PubMed Web of Science ®Google Scholar
• Stevens F J, Argon Y. Pathogenic light chains and the B-cell repertoire. Imniunology Today 1999; 20: 451–457
   PubMedGoogle Scholar
• Davis D P, Raffen R, Dul J L, Vogen S, Williamson E K, Stevens F J, Argon Y. Inhibition of amyloid fiber asscmbly by both BiP and its target peptide. Immunity 2000; 13: 433–442
   PubMed Web of Science ®Google Scholar